Sigma Planning Corp Acquires Shares of 3,653 Illumina, Inc. $ILMN

Sigma Planning Corp bought a new position in Illumina, Inc. (NASDAQ:ILMN) in the second quarter, HoldingsChannel.com reports. The fund bought 3,653 shares of the life sciences company’s stock, valued at approximately $642,000.

A number of other large investors also recently modified their holdings of ILMN. Elyxium Wealth LLC bought a new stake in shares of Illumina during the fourth quarter valued at approximately $25,000. Fiduciary Financial Advisors bought a new position in Illumina in the 2nd quarter worth approximately $26,000. Keating Financial Advisory Services Inc. bought a new position in Illumina in the 2nd quarter worth approximately $32,000. Quarry LP acquired a new position in Illumina during the 3rd quarter worth $32,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Illumina during the 4th quarter worth $33,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft cut Illumina to a “hold” rating in a research note on Wednesday, August 5th. Citigroup upped their price target on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research note on Monday, August 3rd. JPMorgan Chase & Co. raised their price target on Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Finally, Guggenheim lifted their price objective on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $188.40.

Illumina Price Performance

Shares of ILMN stock opened at $207.13 on Wednesday. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $231.81. The stock has a market cap of $31.28 billion, a PE ratio of 38.64, a PEG ratio of 3.01 and a beta of 1.46. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The firm’s 50 day moving average price is $195.94 and its two-hundred day moving average price is $157.18.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts forecast that Illumina, Inc. will post 5.36 EPS for the current year.

Insider Buying and Selling

In related news, SVP Christensen Jakob Wedel sold 1,033 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares in the company, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 138,379 shares of the company’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $228.89, for a total value of $31,673,569.31. Following the completion of the sale, the director owned 1,033,910 shares of the company’s stock, valued at $236,651,659.90. This represents a 11.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,799,688 shares of company stock valued at $379,517,231 over the last three months. Company insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.